A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...

We'll know more about the company's medium-term prospects by the end of the year.

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...

The company's strong cash position gives investors confidence in the gene-editing stock.

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $52.06, marking a +2.1% move from the previous day. This change outpaced the S&P 500's 0.49% loss on the day. Elsewhere, the Dow ...